Logos Global Management LP Lowers Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Logos Global Management LP decreased its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 62.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 595,000 shares of the company’s stock after selling 979,220 shares during the quarter. Enliven Therapeutics accounts for about 1.1% of Logos Global Management LP’s holdings, making the stock its 25th biggest holding. Logos Global Management LP owned about 1.26% of Enliven Therapeutics worth $13,905,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Janus Henderson Group PLC lifted its position in shares of Enliven Therapeutics by 74.8% during the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after buying an additional 305,397 shares during the last quarter. First Turn Management LLC acquired a new position in Enliven Therapeutics in the second quarter valued at $9,657,000. Baker BROS. Advisors LP acquired a new position in Enliven Therapeutics in the first quarter valued at $2,020,000. Bank of New York Mellon Corp boosted its stake in Enliven Therapeutics by 49.2% in the second quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock valued at $2,667,000 after acquiring an additional 37,632 shares in the last quarter. Finally, Nicholas Investment Partners LP acquired a new position in Enliven Therapeutics in the second quarter valued at $1,310,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Insider Buying and Selling

In related news, CFO Benjamin Hohl sold 4,250 shares of the firm’s stock in a transaction that occurred on Thursday, June 27th. The shares were sold at an average price of $22.57, for a total transaction of $95,922.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 12,000 shares of the stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $22.49, for a total transaction of $269,880.00. Following the transaction, the insider now owns 1,077,936 shares of the company’s stock, valued at $24,242,780.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Benjamin Hohl sold 4,250 shares of the stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $22.57, for a total transaction of $95,922.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 123,805 shares of company stock worth $3,068,192. 29.20% of the stock is owned by insiders.

Enliven Therapeutics Price Performance

ELVN stock opened at $23.57 on Tuesday. The company’s 50 day simple moving average is $23.02 and its 200-day simple moving average is $21.31. The firm has a market capitalization of $1.11 billion, a PE ratio of -12.21 and a beta of 1.09. Enliven Therapeutics, Inc. has a 12 month low of $9.80 and a 12 month high of $27.67.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.17. As a group, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Robert W. Baird began coverage on shares of Enliven Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price objective for the company. HC Wainwright assumed coverage on shares of Enliven Therapeutics in a report on Monday, September 9th. They set a “buy” rating and a $37.00 price target for the company. Finally, Baird R W upgraded shares of Enliven Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.